New hope for advanced anal cancer patients through special access program
NCT ID NCT06910137
Summary
This program provides early access to an immunotherapy drug called retifanlimab, given alongside standard chemotherapy drugs carboplatin and paclitaxel. It's for adults with advanced or spreading squamous cell carcinoma of the anal canal who cannot join other clinical trials or use other available treatments. The goal is to control the cancer in patients who have limited treatment options.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SQUAMOUS CELL CARCINOMA OF THE ANAL CANAL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.